title: Pharmacokinetics of pyrrole-imidazole polyamides after intravenous administration in rat.
abstract: The pharmacokinetics of pyrrole (Py)-imidazole (Im) polyamides was studied in rats after the intravenous administration of these compounds. Py-Im polyamide (A) was composed of Ac-ImPyPy-ImPyPy-beta-Dp (beta: beta-alanine, Dp: N,N-dimethylaminopropylamide). Py-Im polyamide (B) was composed of Ac-PyIm-beta-ImIm-PyPy-beta-PyPy-beta-Dp. Py-Im polyamide (C) was composed of Ac-PyPy-beta-PyImPy-PyPyPy-beta-ImPy-beta-Dp. The molecular weight of Py-Im polyamide (A) was 1035.12, that of Py-Im polyamide (B) was 1422.51 and that of Py-Im polyamide (C) was 1665.78. After the intravenous injection of Py-Im polyamide (A) at 1.3, 2.0, 7.5 and 15.0 mg/kg, Py-Im polyamides (B) and (C) at 1.0, 2.0, 3.0 and 5.0 mg/kg, the average systemic clearance and the volume of distribution at the steady state obtained by a non-compartmental method were in the ranges of 4.6-6.4 ml/min/kg and 244-412 ml/kg, 8.9-10.3 ml/min/kg and 1990-4567 ml/kg, and 7.3-11.9 ml/min/kg and 407-667 ml/kg, respectively. Dose linearity of Py-Im polyamides was observed. The plasma concentration-time profiles after the intravenous administration of Py-Im polyamides (A) and (B) were fitted well by a two-compartment model. Py-Im polyamide (C) was observed at high concentrations in the lungs. The plasma concentration-time profiles after the intravenous administration of Py-Im polyamide (C) were described using a catenary two-compartment model. This model is useful for describing the time course after the administration of high-molecular-weight Py-Im polyamides.
authors.affiliation: Department of Clinical Pharmacokinetics, Nihon University, Chiba, Japan.
authors.forename: Akiko
authors.initials: A
authors.lastname: Fukasawa
authors.forename: Takahiko
authors.initials: T
authors.lastname: Aoyama
authors.forename: Takashi
authors.initials: T
authors.lastname: Nagashima
authors.forename: Noboru
authors.initials: N
authors.lastname: Fukuda
authors.forename: Takahiro
authors.initials: T
authors.lastname: Ueno
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Sugiyama
authors.forename: Hiroki
authors.initials: H
authors.lastname: Nagase
authors.forename: Yoshiaki
authors.initials: Y
authors.lastname: Matsumoto
mesh_terms: D000818:Animals; D004305:Dose-Response Relationship, Drug; D007093:Imidazoles / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics*; D007275:Injections, Intravenous; D008168:Lung / Q000378:metabolism; D008297:Male; D008954:Models, Biological; D008970:Molecular Weight; D009757:Nylons / Q000737:chemistry / Q000493:pharmacokinetics*; D011758:Pyrroles / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics*; D021281:Quantitative Structure-Activity Relationship; D051381:Rats; D017208:Rats, Wistar; D013997:Time Factors; D014018:Tissue Distribution
chemical_list: D007093:Imidazoles; D009757:Nylons; D011758:Pyrroles